Endothelial arginase II and atherosclerosis

Area of Science:

• Cardiovascular Biology
• Endothelial Cell Biology
• Vascular Medicine

Background:

• Atherosclerotic vascular disease is a major cause of death, driven by complex genetic and environmental factors.
• Oxidized low-density lipoprotein (OxLDL) induces pro-atherogenic effects in endothelial cells (ECs), impairing nitric oxide (NO) formation.
• Arginase enzyme activity competes with endothelial NO synthase (eNOS) for L-arginine, impacting NO bioavailability.

Purpose of the Study:

• To investigate the role of arginase in OxLDL-induced endothelial dysfunction.
• To explore arginase as a potential therapeutic target for atherosclerotic vascular disease.

Main Methods:

• Studies involved oxidized LDL (OxLDL) exposure and its effects on endothelial cells.
• Experiments utilized hypercholesterolemic (ApoE(-/-)) mice and arginase II knockout (ArgII(-/-)) mice.
• Assessed endothelial function, vascular stiffness, atherosclerotic plaque burden, and vascular smooth muscle cell proliferation.

Main Results:

• OxLDL activates arginase, leading to L-arginine depletion for eNOS and reduced NO production.
• Arginase activation enhances reactive oxygen species production by eNOS.
• Arginase inhibition or deletion improved endothelial vasorelaxant function, reduced vascular stiffness, and decreased atherosclerotic plaque in mouse models.
• Arginase activation promoted polyamine-dependent vascular smooth muscle cell proliferation and collagen synthesis.

Conclusions:

• Arginase plays a critical role in endothelial dysfunction and the development of atherosclerotic vascular disease.
• Targeting arginase may offer a novel therapeutic strategy for preventing and treating atherosclerosis.